Equities Analysts Offer Predictions for DRTS FY2025 Earnings

Key Points

• HC Wainwright has **lowered** its FY2025 earnings per share estimate for Alpha Tau Medical to **($0.48)**, down from a previous estimate of **($0.47)**.
• The company reported **($0.13)** EPS for its latest quarter, **missing** analysts' consensus estimate of **($0.12)** by **($0.01)**.
• Alpha Tau Medical's stock is currently trading at **$3.25** with a market capitalization of approximately **$275.75 million**.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) - Research analysts at HC Wainwright cut their FY2025 earnings per share estimates for Alpha Tau Medical in a research report issued to clients and investors on Wednesday, August 13th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.48) per share for the year, down from their prior forecast of ($0.47). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Alpha Tau Medical's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Alpha Tau Medical's FY2026 earnings at ($0.47) EPS.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

Alpha Tau Medical Stock Performance

Alpha Tau Medical stock traded down $0.14 during mid-day trading on Friday, reaching $3.12. The company's stock had a trading volume of 39,291 shares, compared to its average volume of 55,367. The company has a market capitalization of $264.64 million, a P/E ratio of -6.50 and a beta of 0.99. Alpha Tau Medical has a 12-month low of $2.11 and a 12-month high of $4.39. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.81 and a current ratio of 10.52. The firm's fifty day moving average price is $3.10 and its two-hundred day moving average price is $2.90.

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of Alpha Tau Medical during the first quarter valued at approximately $53,000. Renaissance Technologies LLC grew its stake in shares of Alpha Tau Medical by 188.7% during the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock valued at $127,000 after purchasing an additional 26,800 shares during the period. Northern Trust Corp grew its position in Alpha Tau Medical by 112.6% during the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company's stock valued at $151,000 after buying an additional 25,770 shares during the period. Finally, Kovitz Investment Group Partners LLC increased its holdings in Alpha Tau Medical by 601.4% during the first quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company's stock valued at $568,000 after buying an additional 194,055 shares during the last quarter. 2.65% of the stock is owned by hedge funds and other institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.